Applied Biosystems to Acquire the Research Products Division of Ambion
News Dec 28, 2005
Applied Biosystems Group, an Applera Corporation business, and Ambion, Inc. have announced that they have signed a definitive agreement whereby Applied Biosystems will acquire the Research Products Division of Ambion, a premium supplier of RNA-based reagents for life science research and drug development, for approximately $273 million in cash.
The transaction is subject to regulatory and other customary closing conditions and is expected to close in the first calendar quarter of 2006.
Ambion's sample prep, RNAi, micro RNA, and gene expression and array products provide Applied Biosystems entry into an estimated $500 million market that is currently growing 10 percent annually.
Ambion's calendar 2005 revenues are estimated to exceed $52 million, 22 percent above the prior year.
Applied Biosystems currently anticipates the acquisition will be slightly accretive on a non-GAAP basis in fiscal 2007, due to transition and integration costs, and accretive in fiscal 2008.
On a GAAP basis, it is expected to be dilutive in fiscal 2006 and 2007 and possibly breakeven or accretive in fiscal 2008.
The exact amount of dilution on a GAAP basis will only be known after Applied Biosystems completes an analysis of the allocation of the purchase price.
"This acquisition is an important component of Applied Biosystems' strategy to drive growth by expanding our consumables product offering," said Catherine M. Burzik, president of Applied Biosystems.
"We are extremely pleased to announce this agreement and look forward to welcoming Ambion's employees to Applied Biosystems. We expect Ambion to become a center of excellence within our consumables business."
William V. Murray, president of the Molecular Biology Division of Applied Biosystems, said, "We see significant revenue, operational, and scientific synergies in combining Ambion with Applied Biosystems."
"Ambion's products should enable Applied Biosystems to offer customers more complete workflow solutions. We believe Ambion's strong brand recognition should help increase sales of both Applied Biosystems and Ambion consumable products via our global channels."
"Also important are Ambion's RNA R&D expertise, consumables manufacturing capabilities, and culture of scientific innovation, all of which should complement our existing strengths."
Matt Winkler, the founder and CEO of Ambion, said, "I am pleased that a highly reputable company like Applied Biosystems has acquired the research division of Ambion."
"It is gratifying to know that the people who helped me build Ambion into a great company will now be part of another great company."
"I anticipate that Ambion and the staff that drove its success will make equally significant contributions to Applied Biosystems."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE